Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 0 037 IN DEXTROSE 10 AND SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 0 037 IN DEXTROSE 10 AND SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE vs POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Potassium chloride replaces potassium ions lost from the body; dextrose provides caloric supplementation and prevents ketosis; sodium chloride maintains electrolyte balance and hydration.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
Intravenous infusion of 0.037% potassium chloride in 10% dextrose and 0.9% sodium chloride. The typical adult dose is 500-1000 mL as a continuous infusion at a rate of 1-2 mL/min (equivalent to 0.37-0.74 mg/min potassium chloride), adjusted based on serum potassium levels, with maximum infusion rate of 10 mEq/h potassium and daily maximum of 200 mEq potassium. Frequency: continuous infusion as needed.
None Documented
None Documented
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateTerminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Potassium: terminal half-life ~2-3 hours in plasma, but whole-body turnover is slower; clinical context: dosing intervals depend on renal function and serum K+ monitoring. Dextrose: rapidly cleared, half-life <15 minutes. Sodium: not applicable as steady-state regulated by renal function.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Potassium: renal excretion (90-95%), with minor fecal (<5%) and negligible biliary elimination. Dextrose: primarily metabolized to CO2 and water. Sodium: renal excretion (95-100%) with minor fecal loss.
Category C
Category A/B
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."